Biogen earnings beat by $0.37, revenue topped estimates

Investing.com – Biogen (NASDAQ: ) reported third quarter EPS of $4.36, $0.37 better than the analyst estimate of $3.99. Revenue for the quarter came in at $2.53B versus the consensus estimate of $2.39B.

Guidance

Biogen sees FY 2023 EPS of $14.50-$15.00

Biogen’s stock price closed at $245.61. It is down -10.26% in the last 3 months and down -13.00% in the last 12 months.

Biogen saw 8 positive EPS revisions and 8 negative EPS revisions in the last 90 days. See Biogen’s stock price’s past reactions to earnings here.

According to InvestingPro, Biogen’s Financial Health score is “great performance”.

Check out Biogen’s , and Biogen’s financials here.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com’s earnings calendar